Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.
Glyceroneogenesis, a metabolic pathway that participates during lipolysis in the recycling of free fatty acids to triglycerides into adipocytes, contributes to the lipid-buffering function of adipose tissue. We investigated whether glyceroneogenesis could be affected by human immunodeficiency virus (HIV) protease inhibitors (PIs) responsible or not for dyslipidemia in HIV-infected patients. We treated explants obtained from subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) depots from lean individuals. We observed that the dyslipidemic PIs nelfinavir, lopinavir and ritonavir, but not the lipid-neutral PI atazanavir, increased lipolysis and decreased glyceroneogenesis, leading to an increased release of fatty acids from SAT but not from VAT. At the same time, dyslipidemic PIs decreased the amount of perilipin and increased interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) secretion in SAT but not in VAT. Parthenolide, an inhibitor of the NFκB pathway, counteracted PI-induced increased inflammation and decreased glyceroneogenesis. IL-6 (100 ng) inhibited the activity of phosphoenolpyruvate carboxykinase, the key enzyme of glyceroneogenesis, in SAT but not in VAT. Our data show that dyslipidemic but not lipid-neutral PIs decreased glyceroneogenesis as a consequence of PI-induced increased inflammation in SAT that could have an affect on adipocytes and/or macrophages. These results add a new link between fat inflammation and increased fatty acids release and suggest a greater sensitivity of SAT than VAT to PI-induced inflammation.
INSERM, UMR-S 938, F-75012, Paris, France.
Stéphanie
S
Leroyer
Camille
C
Vatier
Sarah
S
Kadiri
Joëlle
J
Quette
Charles
C
Chapron
Jacqueline
J
Capeau
Bénédicte
B
Antoine
D000328:Adult; D000069446:Atazanavir Sulfate; D002352:Carrier Proteins; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D015850:Interleukin-6 / Q000378:metabolism; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000378:metabolism*; D061466:Lopinavir; D008297:Male; D019888:Nelfinavir / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D000070778:Perilipin-1; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology; D019438:Ritonavir / Q000494:pharmacology; D012717:Sesquiterpenes / Q000494:pharmacology; D050151:Subcutaneous Fat / Q000187:drug effects / Q000378:metabolism*; D014280:Triglycerides / Q000096:biosynthesis*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D002352:Carrier Proteins; D017320:HIV Protease Inhibitors; D015850:Interleukin-6; D009842:Oligopeptides; D000070778:Perilipin-1; D010750:Phosphoproteins; D011725:Pyridines; D011744:Pyrimidinones; D012717:Sesquiterpenes; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D061466:Lopinavir; C002669:parthenolide; D000069446:Atazanavir Sulfate; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D019888:Nelfinavir; D019438:Ritonavir